Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Summary

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present its transformation and growth strategy at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 4:20 p.m. EDT. The presentation will be accessible via a live audio webcast on Myriad's investor information webpage. Myriad is recognized for developing genetic tests that assess disease risk and guide treatment, significantly enhancing patient care while reducing healthcare costs. It was named among the World’s Most Innovative Companies for 2022 by Fast Company.

SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43^rd Annual Global Healthcare Conference on Monday, June 13, 2022 at 4:20 p.m. EDT.

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.myriad.com.  

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Media Contact:	Investor Contact:
Megan Manzari	Nathan Smith
(385) 318-3718	(801) 505-5067
Megan.Manzari@myriad.com	Nathan.Smith@myriad.com

FAQ

What will Myriad Genetics discuss at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022?

Myriad Genetics will discuss its transformation and growth plan.

How can I access the Myriad Genetics presentation at the Goldman Sachs conference?

The presentation will be available via a live audio webcast on Myriad's investor information section of their website.

What is Myriad Genetics known for?

Myriad Genetics is known for its leadership in genetic testing and precision medicine, specializing in tests that assess disease risk and guide treatment.

When is the Myriad Genetics presentation scheduled at the Goldman Sachs conference?

The presentation is scheduled for June 13, 2022, at 4:20 p.m. EDT.

Why was Myriad Genetics recognized by Fast Company in 2022?

Myriad was recognized for being among the World’s Most Innovative Companies due to its advancements in health and well-being through genetic testing.